Retrospective study identifies tumor size and FIGO stage as key risk factors for prognosis in endometrioid endometrial carcinoma.
Objective To identify independent prognostic factors for endometrioid endometrial carcinoma based on a 10‐year follow‐up Chinese cohort study. Methods This retrospective study included 142 patients diagnosed with endometrioid endometrial carcinoma from 2009 to 2013. Clinical, pathological, and immunohistochemical data were analyzed. Patients were categorized into three outcome groups: no recurrence, recurrence with ongoing survival, and death group. Kaplan–Meier survival analysis and univariate and multivariate Cox proportional hazards regression analysis were conducted to assess disease‐free survival (DFS) and overall survival (OS). Results Advanced FIGO stage and tumor size ≥ 4 cm were independent predictors of poorer OS. Grade 3 histology also independently correlated with reduced survival. For DFS, tumor size ≥ 3 cm and advanced stage were significant risk factors. Progesterone receptor (PR) positivity and lack of lymphovascular space invasion (LVSI) were significantly associated with better prognosis in univariate analysis but were not retained in multivariate models. Conclusions Tumor size and FIGO stage are key prognostic factors for recurrence and mortality in endometrioid endometrial carcinoma. Grade 3 histology further worsens the prognosis. Traditional pathological markers continue to be critical for individualized risk assessment and treatment planning.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: